Crossmark

High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease

Crossref DOI link: https://doi.org/10.1007/s00277-018-3521-4

Published Online: 2018-10-15

Published Print: 2019-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Makishima, Kenichi

Obara, Naoshi

Ishitsuka, Kantaro

Sukegawa, Shinichiro

Suma, Sakurako

Kiyoki, Yusuke

Baba, Naoko

Sakamoto, Tatsuhiro

Kato, Takayasu

Kusakabe, Manabu

Nishikii, Hidekazu

Kurita, Naoki

Yokoyama, Yasuhisa

Sakata-Yanagimoto, Mamiko

Hasegawa, Yuichi

Chiba, Shigeru
License Information

Text and Data Mining valid from 2018-10-15
More Information

Article History

Received: 31 May 2018

Accepted: 8 October 2018

First Online: 15 October 2018

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

: Written informed consent was obtained from the patient.